From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona’s bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona’s universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
AquaVitas, LLC Announces Contract from U.S. Government and Health and Human Services for Nationwide Testing of Wastewater for SARS-CoV-2
Award will fund a collaborative effort between AquaVitas, LLC, the Centers for Disease Control and Prevention and Health and Human Services to identify best practices for wastewater SARS- CoV-2 assessment and subsequent data analytics across the U.S. Phase 1 award will fund assessment of wastewater at up to 100 treatment plants (representing ~10% of the U.S. […]
TEMPE, Ariz.–(BUSINESS WIRE)–Calviri, Inc. (www.calviri.com) announces today the appointment of Michael McCallister to the company’s Board of Directors. Mr. McCallister has a breadth of governance and management experience in multiple industries, including health insurance, financial services, and animal life sciences.
GT Medical Technologies Announces $16 Million Financing to Expand Availability of Targeted Therapy for Patients with Recurrent Brain Tumors
GammaTile Therapy Offers Patients a Proven Option to Slow Brain Tumor Progression, Delay Recurrence and Avoid Additional Trips to the Hospital for Radiation Therapy
Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2 Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients Initial doses of REGEN-COV2 will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S. government allocation program
- Makers & Shakers Week Hosted by Moonshot at NACET
- 12/07/2020 - 12/11/2020
- LSN Fundraising Bootcamp - Keys to Successful Partnering
- CivEx: Luminosity Lab - Finding Solutions for Now and the Future
- AZBio Trailblazer Awards and Legislator Appreciation Event
- AZBioPEERS: Getting Ready for JPM